SVB Leerink

AstraZeneca plc's (NYSE: AZN) prospects at being the first mover in the competition to develop a coronavirus vaccine have dimmed, according to an analyst at SVB Leerink. The AstraZeneca Analyst: Andrew Berens has an Outperform rating on AstraZeneca with a $65 price target. The...

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas. The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.  SVB Leerink analyst Mani...

Shares of small-cap biopharma Marinus Pharmaceuticals Inc (NASDAQ: MRNS) were moving sharply higher to a new 52-week high Tuesday following the release of positive results for ganaxolone, the only investigational asset in its pipeline. What Happened: Randor, Pennsylvania-based Marinus said its...

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...

Moderna Inc (NASDAQ: MRNA) shares, which shed over 13% Tuesday on an analyst downgrade, are reversing course — with a competitor's clinical woes as the catalyst. The Moderna Analyst: SVB Leerink analyst Mani Foroohar has a Neutral rating on Moderna with a $41 price target. ...

Competitive pressure could impair Moderna Inc's (NASDAQ: MRNA) ability to take advantage of its strong position in the coronavirus vaccine race, according to an analyst at SVB Leerink. The Moderna Analyst: Mani Foroohar downgraded Moderna from Market Perform to Underperform and lowered the...

Amarin Corporation plc (NASDAQ: AMRN) shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway.  What Happened: Amarin appealed against a late March ruling that its Vascepa patents were invalid. The invalidation of the patents...

Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained a Market Perform rating on Moderna with a $58 price target.  Morgan Stanley analyst...

Shares of catalyst-rich pharma Merck & Co., Inc. (NYSE: MRK) are poised for further upside, according to an analyst at SVB Leerink. The Merck Analyst: Daina Graybosch maintained an Outperform rating on Merck and increased the price target from $95 to $100. The Merck Thesis: Merck shares are...

Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move. What Happened: Shares of New York-based Immunovant, which focuses on treatment for autoimmune disorders, gap-opened Wednesday's session higher and were seen trading with notable gains. This is despite a...

After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreement with the U.S. government to supply 100 million doses of its coronavirus vaccine candidate mRNA-1273 for $1.525 billion. The Moderna...

Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day. What Happened: The FDA accepted the aducanumab biologics license application for priority...

Moderna Inc (NASDAQ: MRNA) shares were moving to the downside Wednesday despite the coronavirus vaccine developer reporting forecast-beating second-quarter results and reports of a potential deal with the Swiss government. Moderna's Q2 Report: Cambridge, Massachusetts-based Moderna said...

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...